Xilio Therapeutics, Inc. (XLO)
NASDAQ · Healthcare
Xilio Therapeutics, Inc. annual/quarterly shareholder equity history from 2024 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Xilio Therapeutics, Inc. shareholder equity for the quarter ending December 31, 2025 were 35.3M, a 100.44% increase year-over-year.
- Xilio Therapeutics, Inc. shareholder equity for 2025 were 35.3M, a 100.44% increase from 2024.
- Xilio Therapeutics, Inc. shareholder equity for 2024 were 17.6M.
Shareholder Equity
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
| Xilio Therapeutics, Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $35 |
| 2024 | $18 |
| Xilio Therapeutics, Inc. Quarterly Shareholder Equity (Millions of US $) | |
|---|---|
| 2025-12-31 | $35 |
| 2024-12-31 | $18 |
Xilio Therapeutics, Inc. Shareholder Equity — FAQ
Xilio Therapeutics, Inc. (XLO) shareholder equity over the last 2 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see XLO's shareholder equity history?
The chart and table above show Xilio Therapeutics, Inc.'s shareholder equity by year and by quarter, including the growth rate.